Myeloid-derived suppressor cells (MDSCs) are a naturally occurring population of immune regulatory cells that suppress the activity of T cells and a range of other immune cell types. The robust immunosuppressive activity of MDSCs is key to several physiological and pathophysiological conditions and may be therapeutically beneficial for treating immune diseases.
Using our iPSC platform, we have developed a proprietary, efficient and reproducible differentiation process to create a homogeneous population of iPSC-derived MDSCs. Our lead MDSC candidate, FT301, is an off-the-shelf, immuno-regulatory cell product candidate with a differentiated profile, including a novel mechanism of action that we believe has broad potential in multiple immune disease indications, including graft-versus-host disease, multiple sclerosis, ulcerative colitis and others.
We have shown in preclinical studies that FT301 potently suppresses T-cell proliferation and activity in vitro and attenuates disease in a xenogenic model of graft-versus-host disease. Importantly, these immuno-regulatory properties of FT301 have been shown to be independent of immunological matching, thus enabling an off-the-shelf therapeutic approach.